TWI719209B - 嘧啶酪氨酸激酶抑制劑 - Google Patents

嘧啶酪氨酸激酶抑制劑 Download PDF

Info

Publication number
TWI719209B
TWI719209B TW106116775A TW106116775A TWI719209B TW I719209 B TWI719209 B TW I719209B TW 106116775 A TW106116775 A TW 106116775A TW 106116775 A TW106116775 A TW 106116775A TW I719209 B TWI719209 B TW I719209B
Authority
TW
Taiwan
Prior art keywords
patent application
compound
scope
item
amino
Prior art date
Application number
TW106116775A
Other languages
English (en)
Chinese (zh)
Other versions
TW201805279A (zh
Inventor
T 哈柏金布萊恩
科隆派翠克
R 查提摩西
J 傑金斯崔西
凱席衛
辛翔林
A 米勒羅斯
湯普森安德魯
Original Assignee
美商百健Ｍａ公司
美商桑西斯醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商百健Ｍａ公司, 美商桑西斯醫藥公司 filed Critical 美商百健Ｍａ公司
Publication of TW201805279A publication Critical patent/TW201805279A/zh
Application granted granted Critical
Publication of TWI719209B publication Critical patent/TWI719209B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
TW106116775A 2012-06-08 2013-06-07 嘧啶酪氨酸激酶抑制劑 TWI719209B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261657360P 2012-06-08 2012-06-08
US61/657,360 2012-06-08

Publications (2)

Publication Number Publication Date
TW201805279A TW201805279A (zh) 2018-02-16
TWI719209B true TWI719209B (zh) 2021-02-21

Family

ID=49712704

Family Applications (3)

Application Number Title Priority Date Filing Date
TW106116775A TWI719209B (zh) 2012-06-08 2013-06-07 嘧啶酪氨酸激酶抑制劑
TW110102365A TWI792158B (zh) 2012-06-08 2013-06-07 嘧啶酪氨酸激酶抑制劑
TW102120447A TWI592406B (zh) 2012-06-08 2013-06-07 嘧啶酪氨酸激酶抑制劑

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW110102365A TWI792158B (zh) 2012-06-08 2013-06-07 嘧啶酪氨酸激酶抑制劑
TW102120447A TWI592406B (zh) 2012-06-08 2013-06-07 嘧啶酪氨酸激酶抑制劑

Country Status (30)

Country Link
US (6) US9394277B2 (cg-RX-API-DMAC7.html)
EP (3) EP2858499B1 (cg-RX-API-DMAC7.html)
JP (6) JP6214643B2 (cg-RX-API-DMAC7.html)
KR (4) KR102468430B1 (cg-RX-API-DMAC7.html)
CN (3) CN113549055A (cg-RX-API-DMAC7.html)
AR (1) AR091273A1 (cg-RX-API-DMAC7.html)
AU (5) AU2013271407B2 (cg-RX-API-DMAC7.html)
BR (2) BR122021002178B1 (cg-RX-API-DMAC7.html)
CA (2) CA3108186A1 (cg-RX-API-DMAC7.html)
CY (1) CY1120638T1 (cg-RX-API-DMAC7.html)
DK (1) DK2858499T3 (cg-RX-API-DMAC7.html)
EA (2) EA027823B1 (cg-RX-API-DMAC7.html)
ES (2) ES2684268T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20181294T1 (cg-RX-API-DMAC7.html)
HU (1) HUE039897T2 (cg-RX-API-DMAC7.html)
IL (2) IL235938B (cg-RX-API-DMAC7.html)
IN (1) IN2014DN10576A (cg-RX-API-DMAC7.html)
LT (1) LT2858499T (cg-RX-API-DMAC7.html)
MX (2) MX385593B (cg-RX-API-DMAC7.html)
NZ (1) NZ702715A (cg-RX-API-DMAC7.html)
PH (2) PH12018501463B1 (cg-RX-API-DMAC7.html)
PL (1) PL2858499T3 (cg-RX-API-DMAC7.html)
PT (1) PT2858499T (cg-RX-API-DMAC7.html)
RS (1) RS57978B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201408173WA (cg-RX-API-DMAC7.html)
SI (1) SI2858499T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800442T1 (cg-RX-API-DMAC7.html)
TW (3) TWI719209B (cg-RX-API-DMAC7.html)
WO (1) WO2013185084A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201409255B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI557127B (zh) 2009-09-04 2016-11-11 百健Ｍａ公司 布魯頓氏酪胺酸激酶抑制劑
US9273028B2 (en) 2010-10-29 2016-03-01 Biogen Ma Inc. Heterocyclic tyrosine kinase inhibitors
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
WO2013185082A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Inhibitors of bruton's tyrosine kinase
HRP20181109T1 (hr) * 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
WO2015151006A1 (en) 2014-03-29 2015-10-08 Lupin Limited Substituted purine compounds as btk inhibitors
WO2015170266A1 (en) 2014-05-07 2015-11-12 Lupin Limited Substituted pyrimidine compounds as btk inhibitors
HUE050592T2 (hu) 2014-10-24 2020-12-28 Bristol Myers Squibb Co Indol karboxamid vegyületek, amelyek hasznosak kináz inhibitorokként
CN110049976A (zh) 2016-07-21 2019-07-23 比奥根Ma公司 布鲁顿氏酪氨酸激酶抑制剂的琥珀酸盐形式和组合物
WO2019208805A1 (ja) 2018-04-27 2019-10-31 小野薬品工業株式会社 Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
CA3224985C (en) 2018-07-31 2025-11-18 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
EP4313023A1 (en) 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023081709A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Vecabrutinib for the treatment of graft-versus-host disease
CA3241069A1 (en) 2021-12-14 2023-06-22 Adrianus Petrus Antonius De Man Macrocyclic btk inhibitors
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029046A1 (en) * 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Bruton's tyrosine kinase inhibitors
TWI592406B (zh) * 2012-06-08 2017-07-21 百健Ｍａ公司 嘧啶酪氨酸激酶抑制劑

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1624A (en) * 1840-06-10 Cooking-stove
US4528138A (en) 1984-06-20 1985-07-09 E. R. Squibb & Sons, Inc. 16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE69212850T2 (de) 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6919178B2 (en) 2000-11-21 2005-07-19 Sunesis Pharmaceuticals, Inc. Extended tethering approach for rapid identification of ligands
CN1481377A (zh) 2000-03-17 2004-03-10 ����˹�ж�-����˹˹����ҩƷ��˾ 作为基质金属蛋白酶和TNF-α的抑制剂的环β-氨基酸衍生物
MY145722A (en) 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
EP1294724B1 (en) 2000-06-26 2006-04-19 Pfizer Products Inc. Pyrrolo¬2,3-d|pyrimidine compounds as immunosuppressive agents
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
WO2003037271A2 (en) * 2001-10-30 2003-05-08 Millennium Pharmaceuticals,Inc. Compounds, pharmaceutical compositions and methods of use therefor
EP1442039A1 (en) 2001-10-31 2004-08-04 Bayer HealthCare AG Pyrimido (4,5-b) indole derivatives
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
ES2344007T3 (es) 2003-10-14 2010-08-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibidores proteina quinasa.
US20080253960A1 (en) * 2004-04-01 2008-10-16 The Trustees Of The University Of Pennsylvania Center For Technology Transfer Lipoprotein-Based Nanoplatforms
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
TW200621760A (en) 2004-09-09 2006-07-01 Mitsubishi Pharma Corp 2-morpholino-4-pyrimidone compound
DE602005023763D1 (de) * 2004-11-04 2010-11-04 Vertex Pharma Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
ES2435790T3 (es) 2004-12-03 2013-12-23 Intervet International B.V. Piperazinas sustituidas como antagonistas de CB1
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス， インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
WO2006091450A1 (en) * 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
US20060281764A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
US20060281700A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
MX391408B (es) 2005-11-01 2025-03-21 Impact Biomedicines Inc Inhibidores de biaril meta-pirimidina de cinasas.
PE20071162A1 (es) * 2005-12-21 2007-11-30 Schering Corp Combinacion de un antagonista/agonista inverso de h3 y un supresor del apetito
WO2008005368A2 (en) 2006-06-30 2008-01-10 Abbott Laboratories Piperazines as p2x7 antagonists
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
US20090325948A1 (en) 2006-07-26 2009-12-31 Timothy Brian Hurley Inhibitors of undecaprenyl pyrophosphate synthase
WO2008033858A2 (en) 2006-09-11 2008-03-20 Cgi Pharmaceuticals, Inc. Kinase inhibitors, and methods of using and identifying kinase inhibitors
NZ601278A (en) 2006-09-22 2013-09-27 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
CN101674831A (zh) * 2007-03-02 2010-03-17 先灵公司 用于治疗糖尿病或疼痛的哌啶基哌啶和哌嗪基哌啶
EP2125819B1 (en) 2007-03-21 2014-10-22 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
CN101932580B (zh) 2007-06-01 2013-05-22 葛兰素史密丝克莱恩有限责任公司 咪唑并吡啶激酶抑制剂
CA2710462C (en) 2008-02-05 2015-11-24 F. Hoffmann-La Roche Ag Pyridinones and pyridazinones
JP2011519049A (ja) 2008-04-29 2011-06-30 イミューンエクサイト インコーポレイテッド 免疫調節組成物およびその使用方法
MX2011000661A (es) 2008-07-16 2011-05-25 Pharmacyclics Inc Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos.
WO2010068788A1 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
WO2010080481A1 (en) * 2008-12-19 2010-07-15 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
US9266890B2 (en) * 2009-01-06 2016-02-23 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
ES2565205T3 (es) 2009-05-25 2016-04-01 Sandoz Ag Método para la producción de ceftobiprol medocaril
EP2485589A4 (en) 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYL-BTK INHIBITORS
US8685880B2 (en) * 2010-06-30 2014-04-01 Chevron U.S.A. Inc. On-site drying of aqueous salt for ionic liquid make-up
US9273028B2 (en) 2010-10-29 2016-03-01 Biogen Ma Inc. Heterocyclic tyrosine kinase inhibitors
WO2013185082A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Inhibitors of bruton's tyrosine kinase
US10280169B2 (en) 2013-12-11 2019-05-07 Biogen Ma Inc. Biaryl bruton's tyrosine kinase inhibitors
HRP20181109T1 (hr) 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
US20170298446A1 (en) 2014-10-03 2017-10-19 Ohio State Innovation Foundation Biomarkers of bruton tyrosine kinase inhibitor resistance
CN110049976A (zh) * 2016-07-21 2019-07-23 比奥根Ma公司 布鲁顿氏酪氨酸激酶抑制剂的琥珀酸盐形式和组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029046A1 (en) * 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Bruton's tyrosine kinase inhibitors
TWI592406B (zh) * 2012-06-08 2017-07-21 百健Ｍａ公司 嘧啶酪氨酸激酶抑制劑

Also Published As

Publication number Publication date
KR102468430B1 (ko) 2022-11-21
EP3753934A1 (en) 2020-12-23
NZ702715A (en) 2016-11-25
JP2017193583A (ja) 2017-10-26
CA3108186A1 (en) 2013-12-12
EA201492056A1 (ru) 2015-05-29
WO2013185084A1 (en) 2013-12-12
SMT201800442T1 (it) 2018-09-13
EA201790418A1 (ru) 2017-11-30
KR20150036020A (ko) 2015-04-07
TW201410668A (zh) 2014-03-16
BR112014030655A8 (pt) 2018-01-02
AU2019203476A1 (en) 2019-06-06
AU2022275504A1 (en) 2023-01-05
PL2858499T3 (pl) 2019-03-29
RS57978B1 (sr) 2019-01-31
ZA201409255B (en) 2015-12-23
AU2017201536B2 (en) 2019-03-07
KR20210072139A (ko) 2021-06-16
BR122021002178B1 (pt) 2022-03-22
US9944622B2 (en) 2018-04-17
IL235938A0 (en) 2015-02-01
CN113549055A (zh) 2021-10-26
JP2021073299A (ja) 2021-05-13
JP6214643B2 (ja) 2017-10-18
US20210017155A1 (en) 2021-01-21
TWI592406B (zh) 2017-07-21
PH12018501463A1 (en) 2019-03-04
US20240417389A1 (en) 2024-12-19
TW201805279A (zh) 2018-02-16
EP2858499B1 (en) 2018-05-16
BR112014030655A2 (pt) 2017-06-27
HUE039897T2 (hu) 2019-02-28
SI2858499T1 (sl) 2018-10-30
US9394277B2 (en) 2016-07-19
SG10201708535UA (en) 2017-11-29
IL277951A (en) 2020-11-30
EP3385263A1 (en) 2018-10-10
CA2875799A1 (en) 2013-12-12
JP2015518903A (ja) 2015-07-06
EP3385263B1 (en) 2020-07-22
JP2023052415A (ja) 2023-04-11
AU2013271407B2 (en) 2016-12-08
DK2858499T3 (en) 2018-08-20
BR112014030655B1 (pt) 2021-04-20
HRP20181294T1 (hr) 2018-10-05
KR20220154850A (ko) 2022-11-22
US20190047986A1 (en) 2019-02-14
SG11201408173WA (en) 2015-01-29
CN104540385A (zh) 2015-04-22
AU2013271407A1 (en) 2015-01-22
EP2858499A4 (en) 2016-01-20
US20150158843A1 (en) 2015-06-11
KR20200043497A (ko) 2020-04-27
US10618887B2 (en) 2020-04-14
US20230174511A1 (en) 2023-06-08
IL235938B (en) 2020-10-29
JP2019077728A (ja) 2019-05-23
PH12014502699B1 (en) 2015-02-02
JP2021073298A (ja) 2021-05-13
LT2858499T (lt) 2018-09-10
MX2014015044A (es) 2015-09-22
CN109305959B (zh) 2022-02-08
AU2019203476B2 (en) 2021-01-28
KR102102587B1 (ko) 2020-04-22
CY1120638T1 (el) 2019-12-11
CN104540385B (zh) 2018-06-05
TWI792158B (zh) 2023-02-11
MX2019003618A (es) 2019-07-18
PT2858499T (pt) 2018-10-24
ES2834333T3 (es) 2021-06-17
CA2875799C (en) 2021-03-23
ES2684268T3 (es) 2018-10-02
CN109305959A (zh) 2019-02-05
AU2021202412A1 (en) 2021-05-20
AU2017201536A1 (en) 2017-03-23
EA027823B1 (ru) 2017-09-29
PH12014502699A1 (en) 2015-02-02
MX363672B (es) 2019-03-29
HK1209284A1 (en) 2016-04-01
TW202142535A (zh) 2021-11-16
US20160304494A1 (en) 2016-10-20
MX385593B (es) 2025-03-18
EP2858499A1 (en) 2015-04-15
PH12018501463B1 (en) 2024-03-27
IN2014DN10576A (cg-RX-API-DMAC7.html) 2015-08-28
AR091273A1 (es) 2015-01-21

Similar Documents

Publication Publication Date Title
TWI719209B (zh) 嘧啶酪氨酸激酶抑制劑
HK40043767A (en) Pyrimidinyl derivatives useful as tyrosine kinase inhibitors
HK1262106B (en) Pyrimidinyl tyrosine kinase inhibitors
HK1262106A1 (en) Pyrimidinyl tyrosine kinase inhibitors
HK1209284B (zh) 嘧啶基酪氨酸激酶抑制劑

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees